Clinical Trial Update: Neoadjuvant Study of Pyrotinib and Trastuzumab Plus Docetaxel and Carboplatin in HER2 Positive Breast Cancer Patients. [Phase 2]

View source ↗

Summary

Phase 2 neoadjuvant trial evaluating pyrotinib and trastuzumab with docetaxel and carboplatin in HER2-positive breast cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• DOCETAXEL (DOCETAXEL)
• Pyrotinib (pyrotinib)
• Trastuzumab (trastuzumab)

Snippet

Sponsor: Henan Cancer Hospital | Conditions: HER2 Positive Breast Cancer | Phase 2 | Status: COMPLETED